Meiji Seika Pharma group company KM Biologics and Serum Institute of India (SII) are collaborating to transfer technology for the development and manufacture in India of the Japanese encephalitis vaccine currently produced and marketed by KM Biologics in Japan. SII is expected to seek Indian regulatory approval as early as 2027, with the partnership intended to establish local manufacturing and supply of the vaccine for children in India.